Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Xeltis Coronary Artery Bypass Graft (XABG) First in Human (FIH)

NCT: NCT04545112 · ENROLLING_BY_INVITATION

NCT IDNCT04545112
StatusENROLLING_BY_INVITATION
Start Date2020-10-22
Completion2031-12
SponsorXeltis (INDUSTRY)
First posted
Last updated

Brief Summary

A prospective, single arm, non-randomized FIH feasibility study to evaluate the preliminary safety and performance of the XABG technology in patients with multi-vessel atherosclerotic coronary artery disease, scheduled by the local Heart Team to undergo elective coronary artery bypass (CABG) surgery.

Frequently Asked Questions

What is Xeltis Coronary Artery Bypass Graft (XABG) First in Human (FIH)?

Xeltis Coronary Artery Bypass Graft (XABG) First in Human (FIH) is a clinical trial registered under NCT04545112. Current status: ENROLLING_BY_INVITATION.

What is the status of NCT04545112?

The current status of NCT04545112 (Xeltis Coronary Artery Bypass Graft (XABG) First in Human (FIH)) is: ENROLLING_BY_INVITATION.

When did Xeltis Coronary Artery Bypass Graft (XABG) First in Human (FIH) start?

Xeltis Coronary Artery Bypass Graft (XABG) First in Human (FIH) started on 2020-10-22.

Related Devices

PMA P220021Stent graft, bypass, superficial femoral arteryEndologix, LLC

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑